The Exchange has sought clarification from Supriya Lifescience Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The NSE has asked Supriya Lifescience to explain why it did not submit segment-wise details as part of its financial results for the quarter ended 30 September 2025. This requirement stems from Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements. The exchange wants the company to clarify this omission under the SEBI LODR framework. As of now, Supriya Lifescience has not yet responded to the exchange's query.
This appears to be a routine compliance-related query from the exchange and is unlikely to have a material impact on the stock price. Investors should watch for the company's response to ensure there are no deeper financial reporting issues.